electroCore Business Summary

electroCore, Inc. (ECOR) is a commercial-stage bioelectronic medicine company specializing in non-invasive vagus nerve stimulation (nVNS) therapy. The company generates revenue through a dual-track business model: a prescription-based segment featuring its flagship gammaCore device for migraine and cluster headaches and the Quell neurostimulator for fibromyalgia, alongside a consumer wellness segment marketed under the Truvaga and TAC-STIM brands. Revenue is primarily derived from direct sales to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD), as well as direct-to-consumer (DTC) channels and retail partnerships via platforms like Amazon. In the competitive landscape of neuromodulation and neurotherapeutics, electroCore competes with firms such as NeuroNascent, Neurona Therapeutics, and CuraSen, positioning itself as a leader in portable, non-invasive bioelectronic devices that provide drug-free alternatives to traditional pharmaceutical interventions for chronic pain. The leadership team is anchored by CEO Daniel S. Goldberger, who brings over 35 years of medical device experience from roles at Repro Med Systems and Xtant Medical, and CFO Joshua Lev, who oversees financial strategy and business development. The company was co-founded by Chief Medical Officer Peter S. Staats, MD, an internationally recognized expert who previously founded the Division of Pain Medicine at Johns Hopkins University, and Chairman Thomas J. Errico, MD, a prominent spinal surgeon and principal investor. The board of directors includes high-level expertise from the technology and pharmaceutical sectors, notably James C. Theofilos, a senior finance leader in Microsoft’s AI division, and David Rubin of the Merck Global Health Innovation Fund. Significant institutional backing is provided by the Merck Global Health Innovation Fund and AWM Investment Company, reflecting strong industry confidence in the company's bioelectronic platform.